Charter Communications Inc vs TransMedics Group Inc — how do they compare? Charter Communications Inc trades at $150.5 (market cap $18.81B), while TransMedics Group Inc trades at $87.42 (market cap $3.10B). The key difference: Charter Communications Inc is far larger — about 6.1× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| CHTR | TMDX | |
|---|---|---|
Market Cap | $18.81B | $3.10B |
Sector | Media | Technology |
52-Week High | $282.74 | $150.42 |
52-Week Low | $123.31 | $61.99 |
Enterprise Value | $115.01B | $3.49B |
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $149.86, down 2.24% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits low valuation multiples with a P/E of 4.1 and P/S of 0.37, while profitability remains solid with a 9.05% net income margin. Recent Q2 2026 earnings beat estimates, though revenue declined year-over-year, and the company has been active in debt management, pricing $4.75 billion in senior secured notes in early August 2026.
The outlook is mixed; the low valuation presents a potential opportunity, but risks include persistent broadband subscriber losses, high debt levels, and competitive pressures. Analyst consensus leans slightly bullish with a $166.18 price target, though sentiment is cautious due to operational headwinds. The stock's trajectory hinges on reversing subscriber trends and managing leverage effectively.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Trailing returns across standard periods
Latest headlines on both assets
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →